What's breaking now, across thousands of outlets.
A joint research group led by Ryo Tanifuji and Hiroki Oguri from the University of Tokyo and Yoshikazu Tanaka from Tohoku University has visualized SacC, an enzyme that plays a key role in building the complex five-ring core of safracin B. This core structure is shared with trabectedin, a drug used to treat soft tissue sarcoma.
We haven't written up this one. Phys.org has the full story — the link below goes straight to it.
On October 19 the Bright Future Fund with Roche Pharma Vietnam launched the 2026 edition of Joining Hands for Her a yearly breast cancer awareness campaign run in partnership since 2013
ZAP Surgical Secures $36M for Global Expansion ZAP Surgical Systems has secured $36 million in new financing to accelerate its global expansion. The California-based medical technology company announced the funding The post ZAP Surgical Secures $36M to Expand Robotic Brain Surgery appeared first on Ventureburn .
Drugmakers want a say in court to defend a rebate pilot in the 340B drug discount program that hospitals are trying to stop.
Plus news about Longwood's next fund and Ryzumvi's label expansion. EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of 53% of its positions after its…
A public information stand, the reading of a manifesto and a pink balloon release were held in Plaza de la Constitución on 19 October.
Gilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival products. After ...
